Developer docs
API playgroundTry for free, no card

Search company profiles

Great Bay Bio

Full company profile

uuid00029pq

Namestring
Great Bay Bio
Legal namestring
Great Bay Bio Group Limited
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Great Bay Bio (GBB) is a Hong Kong-headquartered biopharmaceutical technology company founded in 2019, operating from a 3,000 m² R&D and CMC facility at Hong Kong Science Park. The company develops and commercializes an integrated AI+CMC platform — branded the "Alfa-ecosystem" — comprising four proprietary technology platforms: AlfaBodY (AI-enabled structure-based antibody sequence design with closed-loop dry-wet iteration cycles), AlfaDAX (AI-powered sequence optimization for simultaneous humanization, affinity, and developability assessment), AlfaCell (AI-enabled site-specific integration cell line development described as the first commercially available SSI technology globally), and AlfaMedX (AI-enabled cell culture media development backed by a 10,000+ formulation database). Supporting tools include AlfaStaX for cell line stability prediction, AlfaOPA for no-screening media development, Alfaexpress for transient protein expression, and Klone4.0 for early-stage clone selection. The platform is patent-protected with nearly 100 patents filed and FTO clearance in the US and China; AlfaMedX-K1 has completed FDA Drug Master File filing. The Alfa-ecosystem claims to compress DNA-to-IND timelines from the industry-standard 18-24 months to approximately 10 months, with average AlfaCell titers above 6.9 g/L and bispecific antibody correct pairing rates of 84-100%.

GBB serves two primary enterprise customer segments: biopharmaceutical companies developing monoclonal antibodies, bispecific antibodies, ADCs, fusion proteins, and nanobodies (from molecule design through IND), and CDMOs/CROs seeking AI-enabled differentiation. Revenue is generated through three streams: (1) project-based platform services covering cell line development, antibody discovery, sequence optimization, and media development with quote-based custom pricing, (2) catalog culture media product sales (AlfaMedX-K1 and feed supplements) with ISO 9001:2015 certified production at 250,000 L/year capacity, and (3) licensing royalties — including an undisclosed Fortune 500 MNC media partnership generating global royalty distributions. GTM is enterprise field-sales driven, leveraging direct BD outreach, conference presence (BIO International, BPI, BIONNOVA, ASGH), and channel partnerships with CDMOs ChemPartner and Cheerland Life Science to deliver integrated AI-to-GMP solutions. Disclosed commercial traction includes 50+ completed AlfaCell projects at 89% delivery success rate, and partnerships spanning Asia, North America, Europe, and the Middle East.

As of late 2024 the company had raised approximately USD 28.8M across disclosed funding rounds (USD 3.8M convertible note in 2021 led by Alibaba Hong Kong Entrepreneurs Fund; ~USD 10M Series A in 2021 led by Proxima Ventures; USD 15M Pre-Series B in 2022 led by Tiger Jade Capital with MNC participation; Series B first close in December 2024 led by Tiger Jade Pebble Accelerator). The company employs 101-250 staff and is led by co-founders Kingsley Leung (Chairman) and Dr. Michael Chen (CEO), with supporting executives covering commercial, finance, and CMC functions. Recognition includes EY Entrepreneur of the Year 2023, Forbes Asia 100 to Watch 2024, and HKSTP Elite Programme admission.

Short descriptiontext

Great Bay Bio is a Hong Kong-based biopharmaceutical technology company developing an integrated AI+CMC platform — AlfaBodY, AlfaDAX, AlfaCell, and AlfaMedX — for antibody design, sequence optimization, site-specific integration cell line development, and cell culture media formulation, serving biopharma companies and CDMOs globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHong Kong, Hong Kong SAR China
HQ citystring
Hong Kong
HQ countrystring
Hong Kong SAR China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI bioprocessing platforms, cell line development, antibody discovery services, cell culture media, biologics CMC solutions
Industry4 codes
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAA
Upstream Bioprocessing Systems & Equipment (cell culture/fermentation, bioreactors, feeds/media)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
AI-enabled Biologics CMC Software & Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Technology Licensing & CDMO Services
TypeProfessional Services
Description

GBB provides AI-enabled cell line development, antibody discovery, sequence optimization, and culture media development services to biopharma companies and CDMOs. Revenue is generated through one-time project fees for platform services (cell line development, antibody engineering, media development) and long-term licensing arrangements including out-licensing and royalty fee distributions based on global sales of developed media formulas.

greatbay-bio.com
2Media Product Sales
TypeHardware Sales
Description

Sale of catalog culture media products (AlfaMedX-K1 and related feed supplements) for CHO-K1 cell lines. Annual production capacity of 250,000 L. Products are sold to biopharma companies for R&D and production use.

greatbay-bio.com
3Licensing Royalties
TypeLicensing Royalties
Description

Royalty fee distribution based on global sales of licensed media formulations and platform technologies. Partnership with MNC includes out-licensing and royalty components.

greatbay-bio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 9 records shown
1GBB
Description

Short-form abbreviation for Great Bay Bio used across the company's communications and branding.

greatbay-bio.com
+8 more records
Core offering1 text field

Great Bay Bio sells an integrated AI-enabled bioprocessing ecosystem (the Alfa-ecosystem) consisting of four proprietary platforms — AlfaBodY for antibody design, AlfaDAX for sequence optimization, AlfaCell for site-specific integration cell line development, and AlfaMedX for cell culture media development. The company delivers these capabilities as platform services, technology licensing, and catalog products (Alfaexpress transient expression kit, AlfaMedX commercial culture media) to biopharmaceutical companies and CDMOs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 10 months DNA to IND vs. traditional 18-24 months
+6 more records
Product overview1 text field

Great Bay Bio offers an integrated AI-powered bioprocessing ecosystem called the Alfa-ecosystem, comprising four core platforms: AlfaBodY (antibody design), AlfaDAX (sequence optimization), AlfaCell (cell line development), and AlfaMedX (culture media development). The ecosystem enables end-to-end drug development from DNA to IND in approximately 10 months. Supporting products include Alfaexpress Transient Expression Kit for rapid protein expression and Commercial Culture Media for CHO-K1 cell lines. Services include antibody discovery, sequence optimization, and cell line development. The platforms integrate AI, big data mining, and automation to address industry pain points of long timelines, high costs, and low success rates in biopharmaceutical development.

Product and service1 record
1AlfaBodY - Antibody Design Platform
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Strategic partnership to advance Hong Kong biopharmaceutical innovation, leveraging combined capabilities in AI-enabled drug development.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-20
Description

Partnership to develop AI-powered antibody discovery model combining GBB's AlfaBodY platform with Eureka Therapeutics' antibody development expertise.

3Global Leading Biosimilar Enterprise (undisclosed)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-20
Description

Strategic partnership to accelerate global adoption of the AlfaCell platform for biosimilar development.

greatbay-bio.com
4Prof. Chen from MIT
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-21
Description

Co-development partnership with MIT professor to develop novel tumor antibody using GBB's AI-enabled platforms.

greatbay-bio.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-07-23
Description

Dr. Michael Chen, CEO, attended Cytiva-hosted industry conference in Shenzhen Bay to present on AI-assisted drug development. GBB presented its full spectrum bioprocessing capabilities from molecular design to CMC stages.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Deepened strategic collaboration using AI to accelerate biopharmaceutical development. Building on prior cooperation to leverage GBB's AI platforms and Chime's biologics manufacturing capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic alliance with MEGAROBO to advance biopharmaceutical innovation capabilities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Signed agreement to co-develop novel weight-loss drugs combining Uni-Bio's drug development pipeline with GBB's AI-enabled platforms.

9Fortune 500 MNC (undisclosed)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-11
Description

Strategic cooperation centered on AI-driven cell culture media development. Project encompasses technology platform access, out-licensing, and royalty fee distribution based on global sales of media formulas. Combines GBB's AlfaMedX AI platform with the MNC's global supply chain management capabilities.

greatbay-bio.com
10Xinyi Technology
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-28
Description

Strategic cooperation with Xinyi Technology to advance AI applications in bioprocessing.

greatbay-bio.com
11Cheerland Life Science
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-28
Description

Strategic alliance combining GBB's AI-enabled CDO platform with Cheerland's commercial-scale CDMO capability (1.31 million liters total production capacity). Jointly promotes AI-enabled commercial scale CDMO with initial focus on Greater Bay Area biopharma industry.

greatbay-bio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-25
Description

Strategic alliance combining GBB's AI-enabled CDO development platform with ChemPartner's comprehensive biological drug CDMO capabilities. Provides an AI-enabled one-stop CMC solution with downstream capabilities including GMP pilot manufacturing and IND package submission. GBB gains access to ChemPartner's cGMP facilities and NMPA/FDA submission experience.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Asia-based AI foundation model company for proteins and biologics discovery. Closest geographic and product competitor to GBB's AI antibody design and biologics optimization offerings.

TypeEmerging player
Description

AI/ML-driven drug discovery platform combining machine learning with biology. While focused on small molecule discovery, it competes for the same AI-biologics enterprise R&D dollars and partnership mindshare.

TypeBroad incumbent
Description

Large synthetic biology platform company serving biotech customers with cell engineering and bioprocess development services. Comparable in applying AI/automation to organism engineering for customer programs.

TypeDirect peer
Description

AI-enabled antibody discovery platform with similar business model of licensing platform technology and developing antibody leads for pharma partners. Comparable in using AI to compress biologics discovery timelines.

TypeBroad incumbent
Description

World's largest biologics CDMO with extensive cell line development, media, and GMP manufacturing services. Direct competitor in cell line platforms and biologics CMC, with greater China market overlap.

TypeDirect peer
Description

AI-driven protein design and optimization platform including antibody engineering capabilities. Comparable in using computational methods to design and optimize therapeutic protein sequences for pharma customers.

TypeDirect peer
Description

AI/ML-based computational platform for molecular design and biologics optimization. Overlaps with GBB's AlfaBodY and AlfaDAX in computational sequence design and developability scoring, and serves pharma/biotech enterprise customers via platform licensing.

TypeBroad incumbent
Description

Global CDMO leader offering cell line development, media, and CMC services that compete with GBB's AlfaCell, AlfaMedX, and downstream CDMO partnerships. Major incumbent investing in AI-enabled biologics development.

TypeBroad incumbent
Description

Larger AI drug discovery platform with broader therapeutic ambition. Competes for AI-bio enterprise mindshare and partnership capital even though primarily small-molecule focused.

TypeEmerging player
Description

Single-cell biology and cell line development instrumentation provider. Adjacent competitor in cell line development workflow automation and clone selection for biologics production.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Great Bay Bio

AI-enabled Biologics CMC Software & Servicesgreatbay-bio.com

Great Bay Bio is a Hong Kong-based biopharmaceutical technology company developing an integrated AI+CMC platform — AlfaBodY, AlfaDAX, AlfaCell, and AlfaMedX — for antibody design, sequence optimization, site-specific integration cell line development, and cell culture media formulation, serving biopharma companies and CDMOs globally.

What Great Bay Bio does

Great Bay Bio (GBB) is a Hong Kong-headquartered biopharmaceutical technology company founded in 2019, operating from a 3,000 m² R&D and CMC facility at Hong Kong Science Park. The company develops and commercializes an integrated AI+CMC platform — branded the "Alfa-ecosystem" — comprising four proprietary technology platforms: AlfaBodY (AI-enabled structure-based antibody sequence design with closed-loop dry-wet iteration cycles), AlfaDAX (AI-powered sequence optimization for simultaneous humanization, affinity, and developability assessment), AlfaCell (AI-enabled site-specific integration cell line development described as the first commercially available SSI technology globally), and AlfaMedX (AI-enabled cell culture media development backed by a 10,000+ formulation database). Supporting tools include AlfaStaX for cell line stability prediction, AlfaOPA for no-screening media development, Alfaexpress for transient protein expression, and Klone4.0 for early-stage clone selection. The platform is patent-protected with nearly 100 patents filed and FTO clearance in the US and China; AlfaMedX-K1 has completed FDA Drug Master File filing. The Alfa-ecosystem claims to compress DNA-to-IND timelines from the industry-standard 18-24 months to approximately 10 months, with average AlfaCell titers above 6.9 g/L and bispecific antibody correct pairing rates of 84-100%.

GBB serves two primary enterprise customer segments: biopharmaceutical companies developing monoclonal antibodies, bispecific antibodies, ADCs, fusion proteins, and nanobodies (from molecule design through IND), and CDMOs/CROs seeking AI-enabled differentiation. Revenue is generated through three streams: (1) project-based platform services covering cell line development, antibody discovery, sequence optimization, and media development with quote-based custom pricing, (2) catalog culture media product sales (AlfaMedX-K1 and feed supplements) with ISO 9001:2015 certified production at 250,000 L/year capacity, and (3) licensing royalties — including an undisclosed Fortune 500 MNC media partnership generating global royalty distributions. GTM is enterprise field-sales driven, leveraging direct BD outreach, conference presence (BIO International, BPI, BIONNOVA, ASGH), and channel partnerships with CDMOs ChemPartner and Cheerland Life Science to deliver integrated AI-to-GMP solutions. Disclosed commercial traction includes 50+ completed AlfaCell projects at 89% delivery success rate, and partnerships spanning Asia, North America, Europe, and the Middle East.

As of late 2024 the company had raised approximately USD 28.8M across disclosed funding rounds (USD 3.8M convertible note in 2021 led by Alibaba Hong Kong Entrepreneurs Fund; ~USD 10M Series A in 2021 led by Proxima Ventures; USD 15M Pre-Series B in 2022 led by Tiger Jade Capital with MNC participation; Series B first close in December 2024 led by Tiger Jade Pebble Accelerator). The company employs 101-250 staff and is led by co-founders Kingsley Leung (Chairman) and Dr. Michael Chen (CEO), with supporting executives covering commercial, finance, and CMC functions. Recognition includes EY Entrepreneur of the Year 2023, Forbes Asia 100 to Watch 2024, and HKSTP Elite Programme admission.

Great Bay Bio firmographics

Firmographics
Name
Great Bay Bio
Legal name
Great Bay Bio Group Limited
Website
https://greatbay-bio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Great Bay Bio is a Hong Kong-based biopharmaceutical technology company developing an integrated AI+CMC platform — AlfaBodY, AlfaDAX, AlfaCell, and AlfaMedX — for antibody design, sequence optimization, site-specific integration cell line development, and cell culture media formulation, serving biopharma companies and CDMOs globally.
Ownership category
akta.pro rank

Great Bay Bio industry classification

Industry
Product category
AI-enabled Biologics CMC Software & Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAA
Upstream Bioprocessing Systems & Equipment (cell culture/fermentation, bioreactors, feeds/media)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI bioprocessing platforms
  • Cell line development
  • Antibody discovery services
  • Cell culture media
  • Biologics CMC solutions

Where Great Bay Bio is headquartered

Location

Headquarters

HQ city
Hong Kong
HQ country
Hong Kong SAR China
HQ region
Asia

Offices1 record

Markets served

Great Bay Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Platform Technology Licensing & CDMO Services: GBB provides AI-enabled cell line development, antibody discovery, sequence optimization, and culture media development services to biopharma companies and CDMOs. Revenue is generated through one-time project fees for platform services (cell line development, antibody engineering, media development) and long-term licensing arrangements including out-licensing and royalty fee distributions based on global sales of developed media formulas.
  2. Media Product Sales: Sale of catalog culture media products (AlfaMedX-K1 and related feed supplements) for CHO-K1 cell lines. Annual production capacity of 250,000 L. Products are sold to biopharma companies for R&D and production use.
  3. Licensing Royalties: Royalty fee distribution based on global sales of licensed media formulations and platform technologies. Partnership with MNC includes out-licensing and royalty components.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Great Bay Bio product offering

Product offering

Core offering

Great Bay Bio sells an integrated AI-enabled bioprocessing ecosystem (the Alfa-ecosystem) consisting of four proprietary platforms — AlfaBodY for antibody design, AlfaDAX for sequence optimization, AlfaCell for site-specific integration cell line development, and AlfaMedX for cell culture media development. The company delivers these capabilities as platform services, technology licensing, and catalog products (Alfaexpress transient expression kit, AlfaMedX commercial culture media) to biopharmaceutical companies and CDMOs.

Product overview

Great Bay Bio offers an integrated AI-powered bioprocessing ecosystem called the Alfa-ecosystem, comprising four core platforms: AlfaBodY (antibody design), AlfaDAX (sequence optimization), AlfaCell (cell line development), and AlfaMedX (culture media development). The ecosystem enables end-to-end drug development from DNA to IND in approximately 10 months. Supporting products include Alfaexpress Transient Expression Kit for rapid protein expression and Commercial Culture Media for CHO-K1 cell lines. Services include antibody discovery, sequence optimization, and cell line development. The platforms integrate AI, big data mining, and automation to address industry pain points of long timelines, high costs, and low success rates in biopharmaceutical development.

Differentiator

Problem solved

Functional benefit

Brands

  • GBB: Short-form abbreviation for Great Bay Bio used across the company's communications and branding.
  • AlfaBodY
  • AlfaDAX
  • AlfaCell
  • AlfaMedX
  • AlfaStaX
  • Alfaexpress
  • Klone4.0
  • AlfaOPA

Products and services

  • AlfaBodY - Antibody Design Platform

Quantifiable outcome

  • 10 months DNA to IND vs. traditional 18-24 months
  • +6 more outcomes

Companies that use Great Bay Bio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Great Bay Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Great Bay Bio partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered major, core and minor.

  • TaronmajorStrategic or Co-development Partner · 11 November 2025Strategic partnership to advance Hong Kong biopharmaceutical innovation, leveraging combined capabilities in AI-enabled drug development.
  • Eureka TherapeuticsmajorStrategic or Co-development Partner · 20 June 2025Partnership to develop AI-powered antibody discovery model combining GBB's AlfaBodY platform with Eureka Therapeutics' antibody development expertise.
  • Global Leading Biosimilar Enterprise (undisclosed)coreStrategic or Co-development Partner · 20 May 2025Strategic partnership to accelerate global adoption of the AlfaCell platform for biosimilar development.
  • Prof. Chen from MITminorStrategic or Co-development Partner · 21 January 2025Co-development partnership with MIT professor to develop novel tumor antibody using GBB's AI-enabled platforms.
  • CytivamajorStrategic or Co-development Partner · 23 July 2024Dr. Michael Chen, CEO, attended Cytiva-hosted industry conference in Shenzhen Bay to present on AI-assisted drug development. GBB presented its full spectrum bioprocessing capabilities from molecular design to CMC stages.
  • Chime BiologicsmajorStrategic or Co-development Partner · 1 January 2024Deepened strategic collaboration using AI to accelerate biopharmaceutical development. Building on prior cooperation to leverage GBB's AI platforms and Chime's biologics manufacturing capabilities.
  • MEgarobomajorStrategic or Co-development Partner · 1 January 2024Strategic alliance with MEGAROBO to advance biopharmaceutical innovation capabilities.
  • Uni-Bio / Pebble AcceleratormajorStrategic or Co-development Partner · 1 January 2024Signed agreement to co-develop novel weight-loss drugs combining Uni-Bio's drug development pipeline with GBB's AI-enabled platforms.
  • Fortune 500 MNC (undisclosed)coreStrategic or Co-development Partner · 11 October 2023Strategic cooperation centered on AI-driven cell culture media development. Project encompasses technology platform access, out-licensing, and royalty fee distribution based on global sales of media formulas. Combines GBB's AlfaMedX AI platform with the MNC's global supply chain management capabilities.
  • Xinyi TechnologyminorStrategic or Co-development Partner · 28 April 2023Strategic cooperation with Xinyi Technology to advance AI applications in bioprocessing.
  • Cheerland Life SciencecoreStrategic or Co-development Partner · 28 January 2022Strategic alliance combining GBB's AI-enabled CDO platform with Cheerland's commercial-scale CDMO capability (1.31 million liters total production capacity). Jointly promotes AI-enabled commercial scale CDMO with initial focus on Greater Bay Area biopharma industry.
  • ChemPartnercoreStrategic or Co-development Partner · 25 January 2022Strategic alliance combining GBB's AI-enabled CDO development platform with ChemPartner's comprehensive biological drug CDMO capabilities. Provides an AI-enabled one-stop CMC solution with downstream capabilities including GMP pilot manufacturing and IND package submission. GBB gains access to ChemPartner's cGMP facilities and NMPA/FDA submission experience.

Scale indicators11 records

Recent moves6 records

Expansion highlights7 records

Great Bay Bio competitors and assessment

Company assessment

Direct peers

  • BioMap: Asia-based AI foundation model company for proteins and biologics discovery. Closest geographic and product competitor to GBB's AI antibody design and biologics optimization offerings.
  • AbCellera: AI-enabled antibody discovery platform with similar business model of licensing platform technology and developing antibody leads for pharma partners. Comparable in using AI to compress biologics discovery timelines.
  • Cyrus Biotechnology: AI-driven protein design and optimization platform including antibody engineering capabilities. Comparable in using computational methods to design and optimize therapeutic protein sequences for pharma customers.
  • Schrödinger: AI/ML-based computational platform for molecular design and biologics optimization. Overlaps with GBB's AlfaBodY and AlfaDAX in computational sequence design and developability scoring, and serves pharma/biotech enterprise customers via platform licensing.

Emerging players

  • Insitro: AI/ML-driven drug discovery platform combining machine learning with biology. While focused on small molecule discovery, it competes for the same AI-biologics enterprise R&D dollars and partnership mindshare.
  • PhenomeX (formerly Berkeley Lights): Single-cell biology and cell line development instrumentation provider. Adjacent competitor in cell line development workflow automation and clone selection for biologics production.

Broad incumbents

  • Ginkgo Bioworks: Large synthetic biology platform company serving biotech customers with cell engineering and bioprocess development services. Comparable in applying AI/automation to organism engineering for customer programs.
  • WuXi Biologics: World's largest biologics CDMO with extensive cell line development, media, and GMP manufacturing services. Direct competitor in cell line platforms and biologics CMC, with greater China market overlap.
  • Lonza Group: Global CDMO leader offering cell line development, media, and CMC services that compete with GBB's AlfaCell, AlfaMedX, and downstream CDMO partnerships. Major incumbent investing in AI-enabled biologics development.
  • Recursion Pharmaceuticals: Larger AI drug discovery platform with broader therapeutic ambition. Competes for AI-bio enterprise mindshare and partnership capital even though primarily small-molecule focused.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Great Bay Bio social profiles

Digital presence

Great Bay Bio compliance and trust

Trust signal

Compliance2 records

Great Bay Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Great Bay Bio leadership team

Management profile

Number of profiles

Profiles6 records

Great Bay Bio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Great Bay Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Great Bay Bio

What does Great Bay Bio do?

Great Bay Bio sells an integrated AI-enabled bioprocessing ecosystem (the Alfa-ecosystem) consisting of four proprietary platforms — AlfaBodY for antibody design, AlfaDAX for sequence optimization, AlfaCell for site-specific integration cell line development, and AlfaMedX for cell culture media development. The company delivers these capabilities as platform services, technology licensing, and catalog products (Alfaexpress transient expression kit, AlfaMedX commercial culture media) to biopharmaceutical companies and CDMOs.

Is Great Bay Bio a public or private company?

Great Bay Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Great Bay Bio founded?

Great Bay Bio was founded in 2019. It employs 11 to 50 people.

Where is Great Bay Bio based?

Great Bay Bio is headquartered in Hong Kong, Hong Kong SAR China, in the Asia region.

How does Great Bay Bio make money?

Three revenue lines are on record. Platform Technology Licensing & CDMO Services are the primary driver. The others are media Product Sales and licensing Royalties.

Who are Great Bay Bio's main competitors?

Direct peers on record are BioMap, AbCellera, Cyrus Biotechnology and Schrödinger. Emerging players are Insitro and PhenomeX (formerly Berkeley Lights). Broad incumbents are Ginkgo Bioworks, WuXi Biologics, Lonza Group and Recursion Pharmaceuticals.

Does Great Bay Bio have an API?

No public API is recorded for Great Bay Bio.

What industry is Great Bay Bio in?

Great Bay Bio's product category is AI-enabled Biologics CMC Software & Services. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of HLAAAJAA, Upstream Bioprocessing Systems & Equipment (cell culture/fermentation, bioreactors, feeds/media). Its NAICS code is 325414 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGreat Bay Bio Completes First Close of Series B FinancingGreat Bay Bio closed its first Series B financing round, led by Tiger Jade Pebble Accelerator and its affiliate. The funds will advance its AI-enabled drug development ecosystem, building on its AlfaCell cell line platform that has secured NMPA and FDA approvals. The company aims to accelerate drug development from target identification to pre-clinical candidate in as little as eight months.The Manila TimesGreat Bay Bio Intelligent Drug Development Ecosystem Officially LaunchedGreat Bay Bio launched its Intelligent Drug Development Ecosystem in Suzhou on October 18, 2024. The ecosystem includes platforms like AlfaDAX, AlfaCell, and AlfaMedX, claiming to shorten drug development timelines and increase product yield. The company plans to work with global partners to further transform the biopharmaceutical industry.PR NewswireGreat Bay Bio Intelligent Drug Development Ecosystem Officially LaunchedGreat Bay Bio launched its Intelligent Drug Development Ecosystem in Suzhou on October 18, 2024. The ecosystem includes platforms like AlfaDAX, AlfaCell, and AlfaMedX, claiming to shorten drug development timelines and increase yields. GBB plans to work with global partners to further transform the biopharmaceutical industry.PR NewswireGreat Bay Bio Announces Official Launch of Site-Specific Integration Platform for Cell Line Development, AlfaCell®Great Bay Bio, a Hong Kong-based biotechnology company founded in 2019, announced the official launch of its AI-enabled site-specific integration platform for cell line development called AlfaCell® on October 11, 2022. The platform integrates proprietary AI technologies with cell line development techniques to accurately insert target genes into stable, high-expression "hot spots," significantly reducing time, effort, and cost in the CLD process. The company stated the platform can be applied to various biological drugs including monoclonal antibodies, bispecific antibodies, gene therapy, industrial enzymes, cultured meat, and synthetic biology.FinSMEsGreat Bay Bio Raises USD15M in Pre-Series B FundingGreat Bay Bio raised $15M in pre-Series B funding led by Tiger Jade Capital, with participation from AEF Greater Bay Area Fund and Vectr Ventures. The company will use the funds to accelerate AI-empowered bioprocessing platforms, build production facilities, and establish a global commercial development team.Greatbay-BioAI-enabled CMC + Site-Specific Integration Cell Line Development + Antibody Drug Discovery and Optimization + CHO Cell Culture Media + BiologicsGreat Bay Bio announced on September 13, 2022 the completion of a USD 15 million Pre-series B round led by Tiger Jade Capital, oversubscribed and upsized with participation from AEF Greater Bay Area Fund, Vectr Ventures and a Fortune 500 life science MNC. Funds will fund AI-enabled bioprocessing platforms, production facilities and a global commercial team.FinSMEsGreat Bay Bio Closes Nearly USD10M Series A FundingGreat Bay Bio, a Hong Kong-based biotech, completed a near $10M Series A led by Proxima Ventures. The funds will accelerate global commercialization of its three AI-driven bioprocessing platforms, Klone4.0, AlfaStaX, and AlfaMedX, which have been commercially validated.PR Newswire APACGreat Bay Bio Completes a Near USD 10M Series A FundraisingGreat Bay Bio completed a near $10M Series A fundraising led by Proxima Ventures, oversubscribed with new and existing institutional investors. The funds will accelerate commercialization of three AI-driven bioprocessing platforms: Klone4.0, AlfaStaX, and AlfaMedX, which have been validated to improve efficiency and reduce R&D risk.PR NewswireGreat Bay Bio Completes a Near USD 10M Series A FundraisingGreat Bay Bio has completed a near USD 10 million Series A fundraising round led by Proxima Ventures, with participation from other institutional investors. The capital will be used to accelerate the global commercialization of three AI-driven bioprocessing platforms: Klone4.0, AlfaStaX, and AlfaMedX.PR NewswireGreat Bay Bio Announces Its First AI-enabled Bioprocessing Platform-Klone 4.0, Reducing Cell Line Development Time and Cost by Up to 80%Great Bay Bio announced the launch of Klone 4.0, an AI-enabled bioprocessing platform designed to reduce cell line development time and cost by up to 80%. The company reports that proof-of-concept data shows the technology can identify higher-yielding cell lines significantly faster than traditional methods, potentially disrupting the bioprocessing industry.